|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
21 August 2023 |
|
Main ID: |
NCT01852448 |
|
Date of registration:
|
09/05/2013 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Genetics of Insulin and Incretins in Cystic Fibrosis
|
|
Scientific title:
|
Evaluation of the Enteroinsular Axis in Cystic Fibrosis |
|
Date of first enrolment:
|
May 2013 |
|
Target sample size:
|
550 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT01852448 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Andrea Kelly, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Children's Hospital of Philadelphia |
|
|
Name:
|
Rachel Walega |
|
Address:
|
|
|
Telephone:
|
267-586-5969 |
|
Email:
|
walegar1@chop.edu |
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria
1. Subjects age >2y
2. Diagnosis of Cystic Fibrosis
3. For subjects< 18 years, parental/guardian permission (informed consent) and if
appropriate, child assent
Exclusion Criteria 1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes)
(e.g T1DM)
.
Age minimum:
2 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Cystic Fibrosis
|
|
Intervention(s)
|
|
Genetic: Blood or Saliva Sample Collection
|
|
Primary Outcome(s)
|
|
Blood sample for DNA to genotype TCF7L2 and about 10 other GWAS-implicated T2DM genes.
[Time Frame: 1 day]
|
|
Secondary ID(s)
|
|
12-009589
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|